You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches
Dermatology

Bullous Pemphigoid Mechanism of Disease Video

Explore the mechanism of disease of bullous pemphigoid (BP), including the roles of autoimmunity and type 2 inflammation, in this informative video.

Learning objectives

  • Learn about the mechanism of disease of bullous pemphigoid (BP), including the roles of autoimmunity and type 2 inflammation.

Description

Review this informative video to learn about the mechanism of disease of bullous pemphigoid (BP), including the roles of autoimmunity and type 2 inflammation

Tags
mechanism of disease
MAT-US-2410522 v1.0 - P Exp Date: 10/22/2026

Related resources

Barrier Disruption in Atopic Dermatitis and Food Allergy
Type 2 Inflammation
expert video

Barrier Disruption in Atopic Dermatitis and Food Allergy

Type 2 Inflammation in Atopic Dermatitis and Food Allergy
Type 2 Inflammation
expert video

Type 2 Inflammation in Atopic Dermatitis and Food Allergy

Assessment of Atopic Dermatitis Burden in Children and Adolescents
Dermatology
expert video

Assessment of Atopic Dermatitis Burden in Children and Adolescents

Comorbidities in Children and Adolescents with Atopic Dermatitis
Dermatology
expert video

Comorbidities in Children and Adolescents with Atopic Dermatitis

Atopic Dermatitis as a Risk Factor for Food Allergy
Type 2 Inflammation
expert video

Atopic Dermatitis as a Risk Factor for Food Allergy

What is the disease burden of atopic dermatitis on children and their families
Dermatology
expert video

What is the disease burden of atopic dermatitis on children and their families

The Burden of Disease in Atopic Dermatitis
Dermatology
expert video

The Burden of Disease in Atopic Dermatitis

The Burden of Chronic Spontaneous Urticaria: One Patient’s Journey to Diagnosis
Dermatology
videoanimation

The Burden of Chronic Spontaneous Urticaria: One Patient’s Journey to Diagnosis

Explore the clinical presentations of bullous pemphigoid (BP), the steps for diagnosis, and the burden of disease.
Dermatology
Infographic

Bullous Pemphigoid (BP): Don't Miss the Diagnosis

Navigating Atopic Dermatitis and Hand and Foot Dermatitis: Clinical Manifestations and Pathophysiology
Dermatology
expert video

Navigating Atopic Dermatitis and Hand and Foot Dermatitis: Clinical Manifestations and Pathophysiology

Disease Modification Concepts in AD
Dermatology
expert video

Disease Modification Concepts in AD

Barrier disruption in AD and the development of environmental and food allergies
Dermatology
expert video

Barrier disruption in AD and the development of environmental and food allergies

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis
Dermatology
videoanimation

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

CSU is Associated With a High Burden and Impact on Quality of Life
Dermatology
expert video

CSU is Associated With a High Burden and Impact on Quality of Life

How type 2 cytokines can amplify inflammatory response in CSU
Dermatology
expert video

How type 2 cytokines can amplify inflammatory response in CSU

Type 2 Inflammation and Infections
Type 2 Inflammation
slide presentation

Type 2 Inflammation and Infections

Bullous Pemphigoid Mechanism of Disease Video
Dermatology
videoanimation

Bullous Pemphigoid Mechanism of Disease Video

Diagnosis of Bullous Pemphigoid Interactive Patient Case
Dermatology
interactivity

Diagnosis of Bullous Pemphigoid Interactive Patient Case

Differential Diagnosis and Disease Onset in Older Adult Patients With AD
Dermatology
expert video

Differential Diagnosis and Disease Onset in Older Adult Patients With AD

Importance of Achieving Disease Control in Adults With Moderate-to-Severe AD
Dermatology
expert video

Importance of Achieving Disease Control in Adults With Moderate-to-Severe AD

Inflamm-aging: Systemic Inflammation and Frailty in Older Adults
Dermatology
expert video

Inflamm-aging: Systemic Inflammation and Frailty in Older Adults

Is Pediatric AD Linked to Other Allergic Diseases?
Dermatology
expert video

Is Pediatric AD Linked to Other Allergic Diseases?

Long-term Impacts of AD and the Potential Benefit of Early Intervention
Dermatology
expert video

Long-term Impacts of AD and the Potential Benefit of Early Intervention

New Data on the Systemic (Multi-Organ) Burden of AD in Children and the Need for Early Intervention
Dermatology
expert video

New Data on the Systemic (Multi-Organ) Burden of AD in Children and the Need for Early Intervention

Practical Considerations in Older Patients with AD
Dermatology
expert video

Practical Considerations in Older Patients with AD

The Benefits of Early Intervention in AD: More Than Skin Deep
Dermatology
expert video

The Benefits of Early Intervention in AD: More Than Skin Deep

The Benefits of Early Intervention in AD: More Than Skin Deep – Q&A Session and Conclusion
Dermatology
expert video

The Benefits of Early Intervention in AD: More Than Skin Deep – Q&A Session and Conclusion

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-US-2305040 v3.0-P Exp. Date: 11/24/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region